Significant Ownership of Invus Global Management, LLC

Signature - Title
/s/ Raymond Debbane - Raymond Debbane, President
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Invus Global Management, LLC.

Follow Filing Activity

Follow Invus Global Management, LLC and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Significant Ownership of Invus Global Management, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
LXRX Lexicon Pharmaceuticals, Inc. Common Stock, par value $0.001 per share 39% $273,243,457 +$31,857,907 175,156,062 +13% Artal Participations S.a r.l. 30 Apr 2026
SRRK Scholar Rock Holding Corporation Common Stock, par value $0.001 per share 11% $354,735,676 10,825,013 Invus Public Equities, L.P. 31 Dec 2024
IVA Inventiva S.A. Ordinary shares, nominal value Euro 0.01 per share 11% $49,037,031 +$24,518,517 14,814,813 +100% Invus Public Equities, L.P. 30 Jun 2025
RANI Rani Therapeutics Holdings, Inc. Class A Common Stock, $0.0001 par value 10% $4,910,990 9,825,911 Raymond Debbane 16 Oct 2025
SLDB Solid Biosciences Inc. Common Stock $0.001 par value per share 10% 10,066,682 Raymond Debbane 31 Mar 2026
BCAX Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share 9.6% $50,656,769 5,216,969 Raymond Debbane 30 Jun 2025
SLDB Solid Biosciences Inc. Common Stock, $0.001 par value per share 9.6% $27,216,371 +$13,457,391 7,415,905 +98% Raymond Debbane 31 Mar 2025
VTVT vTv Therapeutics Inc. Class A Common Stock, $0.01 par value per share 9.4% $9,179,310 +$1,051,154 393,098 +13% Raymond Debbane 30 Sep 2025
NBTX Nanobiotix S.A. Ordinary shares, nominal value Euro 0.03 per share 8.9% $13,545,053 4,232,829 Invus Public Equities, L.P. 31 Dec 2023
ENGN enGene Therapeutics Inc. Common Shares 7.8% $35,511,355 +$6,818,136 5,253,159 +24% Raymond Debbane 31 Mar 2026
DBVT DBV Technologies S.A. Ordinary Shares, nominal value Euro 0.10 per share 6.5% $427,523,511 +$109,793,256 19,310,005 +35% Raymond Debbane 31 Mar 2026
OLMA Olema Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share 5.1% $108,693,078 4,461,949 Raymond Debbane 16 Mar 2026
ABVX Abivax S.A. Ordinary Shares, nominal value Euro 0.01 per share 5% $469,347,122 -$177,185,644 3,922,995 -27% Invus Public Equities, L.P. 31 Dec 2025
VIGL Vigil Neuroscience, Inc. Common Stock, par value $0.0001 per share 4.9% $3,563,958 1,991,038 Raymond Debbane 31 Dec 2024
NMRA Neumora Therapeutics, Inc. Common Stock, par value $0.0001 per share 4.7% $16,570,753 -$975,000 8,497,822 -5.6% Raymond Debbane 31 Mar 2026
SEER Seer, Inc. Class A Common Stock, par value $0.00001 per share 4.4% $4,155,157 2,458,673 Invus Public Equities, L.P. 31 Mar 2026
TNGX Tango Therapeutics, Inc. Common Stock, par value $0.001 per share 4% $118,346,637 -$52,472,987 5,657,105 -31% Raymond Debbane 31 Mar 2026
SYRS Syros Pharmaceuticals, Inc. Common Stock, $0.001 par value per share 3.8% $776,595 1,063,829 Invus Public Equities, L.P. 31 Dec 2024
BCYC Bicycle Therapeutics plc Ordinary Shares, nominal value GBP 0.01 per share 3.1% $7,773,192 -$7,909,072 1,560,882 -50% Raymond Debbane 31 Mar 2026
GOSS Gossamer Bio, Inc. Common Stock, par value $0.0001 per share 2.8% $5,507,814 6,258,880 Invus Public Equities, L.P. 31 Dec 2024
TENX Tenax Therapeutics, Inc. Common Stock, $0.0001 par value per share 2.5% $6,390,029 427,141 0% Raymond Debbane 31 Mar 2026
KLRS Kalaris Therapeutics, Inc. Common Stock, $0.0001 par value per share 1.5% $754,533 282,586 Invus Public Equities, L.P. 30 Jun 2025
RZLT Rezolute, Inc. Common Stock, $0.001 par value per share 0% $0 -$11,541,900 0 -100% Invus Public Equities, L.P. 31 Dec 2025

Schedules 13D/G Reported by Invus Global Management, LLC:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .